(Total Views: 294)
Posted On: 09/24/2021 5:45:26 PM
Post# of 36541
The float is reasonable for a non revenue clinical research OTC biotech. As an example CYDY was at similar price levels with nearly 4 times the OS and went to $10. Currently at $2.33 with 645,000,000 in the OS count.
Having said that, I would be very happy for the rest of the financing to come through so we don't continue this dilution.
Having said that, I would be very happy for the rest of the financing to come through so we don't continue this dilution.
(1)
(0)Scroll down for more posts ▼
